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Association between non-alcoholic 
fatty liver disease and coronary 
calcification depending on sex and 
obesity
Seok-hyung Kim1, Hae Yeul park2, Hye Sun Lee3, Kwon Soo Jung2, Moon Hyoung Lee2, 
Jong Hyun Jhee2, tae Hoon Kim4, Jung Eun Lee4, Hyung Jong Kim5, Beom Seok Kim6, 
Hyeong Cheon park2,7, Byoung Kwon Lee2 & Hoon Young choi2,7*
Non-alcoholic fatty liver disease (NAFLD) is considered a hepatic manifestation of metabolic syndrome 
and is associated with cardiovascular outcomes. We investigated whether NAFLD was associated 
with coronary artery calcification (CAC) in participants without a previous history of cardiovascular 
disease and whether this association differed according to sex and obesity status after adjustment for 
other atherosclerosis risk factors, alcohol intake, and liver enzyme levels. Among 67,441 participants, 
data from 8,705 participants who underwent a fatty liver status and CAC assessment during routine 
health screening were analysed. CAC scores were calculated using computed tomography. NAFLD 
was diagnosed in patients with evidence of liver steatosis on ultrasonography. Obesity was defined 
as a body mass index of ≥25 kg/m2. Multivariate analysis showed a significant association between 
NAFLD and CAC in non-obese participants (odds ratio, 1.24 [95% confidence interval, 1.01–1.53]), 
whereas NAFLD and CAC were not associated in obese participants. Interaction analysis showed that 
the association between NAFLD and CAC was influenced by sex and obesity. Subgroup analysis revealed 
a significant association between NAFLD and CAC in non-obese male participants (odds ratio, 1.36 
[1.07–1.75]), but not in female participants. Our study indicates that non-obese men with NAFLD are 
prone to CAC.
Cardiovascular disease (CVD) is a major cause of death, and its contribution to the overall disease burden is 
expected to increase. Therefore, there have been worldwide efforts to identify cardiovascular risk factors1,2.
Obesity is a well-established risk factor for CVD and mortality3; however, recent studies have reported the 
localized distribution of body fat rather than overall obesity4,5. In one study, regional fat distribution was shown to 
have a significant association with the risk of coronary heart disease after adjusting for body mass index (BMI)4.
Non-alcoholic fatty liver disease (NAFLD) can progress to liver cirrhosis and liver cancer, but its clinical 
manifestation is not confined to the liver. Moreover, it has been associated with an increased prevalence and 
incidence of CVD6–8. NAFLD is a highly prevalent metabolic abnormality closely linked to the overweight and 
obesity epidemic8–10. In tertiary liver centres, a majority of patients with NAFLD also have an increased BMI, but 
approximately 1 out of 8 NAFLD patients has normal BMI11. Globally, the prevalence of NAFLD in the non-obese 
population has been widely reported, ranging from 3% to 30%12.
Coronary artery calcification (CAC) is a non-invasive predictor of the burden of coronary atherosclerosis and 
is evaluated using computed tomography (CT). CAC scores have been reported to be associated with increased 
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CVD events13. A previous study has shown that obesity is a risk factor for CAC irrespective of metabolic disor-
ders14. Further, in a large health-screening population, the CAC score was significantly higher in subjects with 
NAFLD than in those with abdominal obesity after adjusting for risk factors for CVD and metabolic syndromes5. 
However, the association between NAFLD and CAC has not been consistently shown across all studies, which 
could be limited by the inadequate adjustment for established cardiovascular risk factors, selection bias, and study 
design15–19.
The present study aimed to investigate whether NAFLD was associated with CAC in participants without a 
previous history of CVD and whether this association differed according to obesity status after adjustment for 
other atherosclerosis risk factors, alcohol intake, and liver enzymes. We also evaluated the association between 
NAFLD and CAC in male and female participants.
Methods
Participants. This retrospective cross-sectional study included adult participants who voluntarily underwent 
health screening examination at Gangnam Severance Hospital from 2005 to 2017. Among 67,441 participants, 
data from 8,705 participants who had been evaluated for CAC and fatty liver status were collected from the med-
ical records database. The study excluded an additional 1,446 participants who (1) had known hepatic disease 
or were positive for serologic markers of viral hepatitis B or C; (2) had excessive alcohol consumption (≥30 g/
day for men and ≥20 g/day for women); (3) had a history of liver cirrhosis or findings of liver cirrhosis on ultra-
sonography; (4) had a history or current diagnosis of malignancy; and/or (5) had a history of CVD. Finally, 7,259 
participants were included in this study (Fig. 1).
This study was performed in accordance with relevant guidelines and regulations. The Institutional Review 
Board of Gangnam Severance Hospital, Yonsei University College of Medicine, approved the study protocol (IRB 
No. 3-2019-0164) and the need for acquisition of informed consent from participants was waived owing to the 
retrospective nature of the study. The present study complied with the Guideline for Good Clinical Practice (GCP) 
by International Council for Harmonization of Technical Requirements for Registration of Pharmaceutical for 
Human use (ICH).
Health screening examination. Health screening examination comprised initial consultation, anthropo-
metric assessments, blood tests, and several imaging studies. Practice nurses collected and coded data on disease 
history, alcohol consumption, and smoking habits through initial consultation with participants. Irrespective 
of specific symptoms, abdominal ultrasound scan was included in all health screening programmes in order to 
detect the disease early. Health screening programmes, including CT coronary angiography, were conducted 
as a preventive measure to identify potential cardiovascular problems in voluntary participants regardless of 
heart-related symptoms.
clinical and laboratory data. We reviewed the participants’ medical records, including height, body 
weight, smoking status, alcohol intake, and blood pressure, which were measured during the visits. Blood sam-
ples were obtained on the day cardiac CT was performed after a fasting period of at least 12 hours. The following 
laboratory parameters were measured: C-reactive protein (CRP), creatinine, fasting glucose, aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GT), and low-density 
lipoprotein (LDL)-cholesterol. LDL-cholesterol was measured directly with a homogenous enzymatic colorimet-
ric assay using a Beckman Coulter AU5800 analyser (Beckman Coulter Inc., Brea CA, USA). BMI was calculated 
as body weight (kilograms) divided by the square of height (meters). Waist-hip-ratio was estimated based on the 
waist and hip circumference measured using bioelectrical impedance analysis (BIA, InBody570; InBody, Seoul, 
All participants assessed by abdominal ultrasonography at 
the Gangnam Severance Hospital check-up from 2005 to 2017 
(n=67,441) 
Excluded (n=1,446) 
• Participants with known hepatic disease or viral hepatitis carrier (e.g., 
positive for HBV or HCV) (n=468)  
• Participants with a history of malignancy (n=269) 
• Participants with a history of liver cirrhosis or findings of liver cirrhosis 
on ultrasonography (n=13) 
• Participants with excessive alcohol consumption (n=739) 
• Participants with a history of cardiovascular disease (n=50) 
Final study participants (n=7,259)
• Participants without CAC (n=5,028) 
• Participants with CAC (n=2,231) 
Participants assessed by both cardiac MDCT and abdominal 
ultrasonography (n=8,705) 
Missing cardiac MDCT data (n=58,736)
Figure 1. Diagram of participant enrolment. MDCT, multidetector computed tomography; HBV, hepatitis B 
virus; HCV, hepatitis C virus; CAC, coronary artery calcification.
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South Korea)20. Obesity was defined as a BMI of ≥25 kg/m2. Abdominal obesity was defined as a waist-hip ratio 
above 0.90 for men and above 0.85 for women. Obesity and abdominal obesity were defined according to the 
criteria given by the World Health Organization; particularly, the definition of obesity was based on specific cri-
teria for Asians21,22. Smoking and alcohol consumption habits were determined from questionnaires. Participants 
were classified as current smokers, or ex-smokers or non-smokers based on their smoking habits. Average alco-
hol consumption per day was calculated using the frequency and amounts of beverages consumed per drinking 
day. Excessive alcohol consumption was defined as average alcohol intake ≥30 g/day for men and ≥20 g/day for 
women23. Patients were classified as drinkers (except those with excessive alcohol consumption) or non-drinkers 
on the basis of current alcohol intake. In this study, NAFLD was described as the presence of steatosis without sec-
ondary causes, such as hepatitis virus infection or excessive alcohol consumption24. Kidney function was assessed 
based on the estimated glomerular filtration rate (eGFR), which was calculated using the CKD-Epidemiology 
Collaboration equation and serum creatinine levels25.
Assessment of coronary calcification and fatty liver status. Participants underwent cardiac multi-
detector CT (Philips Brilliance 64; Philips Medical Systems, Best, The Netherlands), with a 3-mm slice thickness 
and 1.5-mm reconstruction interval. Beta-blocking agents (25 mg atenolol) were administered to participants 
with a heart rate of >66 beats/min prior to CT. The CAC score was measured using the Agatston method26,27. 
CAC scores above zero indicated CAC28.
A diagnosis of fatty liver was based on abdominal ultrasonography using a 3.5-MHz transducer (HDI 5000; 
Philips, Bothell, USA). Ultrasonography was performed by four experienced radiologists who were unaware of 
the aims of the study and blinded to the laboratory findings. Hepatic steatosis was graded according to previ-
ously described criteria as follows: mild steatosis was recognized by slightly increased echogenicity in the liver 
parenchyma with relative maintenance of echogenicity in the walls of the portal veins and hepatorenal contrast; 
moderate steatosis was accompanied by a diffuse increase in parenchymal echogenicity with a loss of echogenicity 
in the wall of the portal veins, particularly from the peripheral branches; and severe steatosis was recognized by 
markedly increased echogenicity in the liver parenchyma with a loss of echogenicity in most of the portal vein 
wall, including the main branches, and a high hepatorenal contrast. In this study, any degree of steatosis in the 
liver was classified as NAFLD without secondary causes, such as hepatitis virus infection or excessive alcohol 
consumption23,24.
Statistical analysis. Data are presented as median (25th to 75th percentile) for continuous variables or as 
frequency (percentage) for categorical variables. Statistical differences in clinical characteristics between the two 
groups were determined using the Mann-Whitney U test for continuous variables and the chi-square test for 
categorical variables. Univariate and multivariate logistic regression analyses with adjustment for the influence of 
confounders were performed to determine the association between CAC and NAFLD according to obesity status.
To test the combined effect of sex, obesity, and NAFLD, we tested their interactions with the interaction term 
for sex*obesity*fatty liver based on binary logistic regression models for outcome. The interaction between sex, 
obesity, and fatty liver was tested at a significance level of 0.1529,30.
Additional subgroup analyses were performed to identify the association between CAC and NAFLD, stratified 
by obesity status and sex after adjustment for multiple cofounders. Odds ratios (ORs) with 95% confidence inter-
vals (CIs) were abstracted from the analysis and used to create a forest plot. Comparisons with P-values < 0.05 
were considered statistically significant.
Mediation analyses were performed to evaluate the proportion of the total effect that could be explained by 
abdominal obesity. To test our main hypothesis, subjects were divided according to obesity or NAFLD status31. 
We assumed that all missing values were completely random and analysed the whole data, with the exception 
of these missing values. All analyses were conducted using the Statistical Package for the Social Sciences (SPSS) 
version 23.0 (IBM Corp., Armonk, NY, USA) and Statistic Analysis System (SAS) version 9.3 (SAS Inc., Cary, 
NC, USA).
Results
Baseline characteristics. The median age and BMI of the 7259 participants were 54 years and 24.1 kg/m2, 
respectively; 59.5% of the participants were males.
The participants were divided into two groups according to obesity status. Obese participants had a signif-
icantly higher prevalence of hypertension, diabetes, dyslipidaemia, and current smoking and current drinking 
status (P < 0.001, except diabetes, P = 0.018; current smoker, P = 0.005). Fasting glucose, LDL-cholesterol, CRP, 
triglyceride, AST, ALT, and γ-GT levels were significantly higher, whereas eGFR was lower in obese participants 
than in non-obese participants (P < 0.001). Obese participants had a significantly higher prevalence of NAFLD, 
abdominal obesity, and CAC than non-obese participants (Table 1).
Non-alcoholic fatty liver disease and coronary calcification. Univariate logistic regression analysis 
was performed to examine the association of individual covariates with CAC in order to identify risk factors 
for CAC. In all participants, all risk factors, including NAFLD, were significantly associated with CAC except 
LDL-cholesterol. In obese participants, increasing age (P < 0.001), male sex (P < 0.001), hypertension (P < 0.001), 
diabetes (P < 0.001), abdominal obesity (P < 0.001), LDL-cholesterol (P = 0.013), eGFR (P < 0.001), and AST 
(P < 0.001) significantly affected CAC. In non-obese participants, increasing age, male sex, hypertension, dia-
betes, abdominal obesity, eGFR (P < 0.001), CRP (P = 0.001), current smoking, AST, ALT, and γ-GT levels 
(P < 0.001) were significantly associated with CAC. NAFLD was significantly associated with CAC in both obese 
(P = 0.011) and non-obese (P < 0.001) participants (Supplementary Table S1).
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Multivariate analysis was performed to investigate which variables were independently associated with CAC 
according to obesity status. Increasing age (P < 0.001), male sex (P < 0.001), hypertension (P < 0.001), diabetes 
(P < 0.001), obesity (P = 0.004), NAFLD (P = 0.001), current smoking (P = 0.011), and AST (P = 0.009) were 
independent predictors of CAC in all participants. Increasing age, male sex, hypertension, diabetes, and AST were 
independently associated with CAC irrespective of obesity. However, abdominal obesity was not independently 
associated with CAC in all participants and obese or non-obese participants (P = 0.428 and P = 0.216, respec-
tively). NAFLD (P = 0.034) was independently associated with CAC only in non-obese participants (Table 2).
Interaction effect and subgroup analysis. The three-way interaction effect, including sex*NAFLD, obe-
sity status*NAFLD, and sex*obesity status*NAFLD, was obtained by analysing the effect of NAFLD and CAC 
according to sex and obesity status. All multinomial logistic regression models showed significant interactions 
for CAC (interaction P = 0.0210 before adjustment, P = 0.1291 in model 1, P < 0.001 in model 2, and P = 0.0002 
in model 3), showing that the association between NAFLD and CAC was influenced by sex and obesity status 
(Table 3).
The forest plot (Fig. 2) illustrates the stratified analysis of the association between NAFLD and CAC among 
sex-stratified participants with and without obesity after sequential adjustments. In models 1, 2, and 3, NAFLD 
was significantly associated with CAC among non-obese male participants (model 1: OR, 1.29 [1.06–1.58], 
P = 0.012; model 2: OR, 1.28 [1.01–1.62], P = 0.039; model 3; OR, 1.36 [1.07–1.75], P = 0.014). However, there 
was no significant association between NAFLD and CAC in female participants with or without obesity.
In a mediation analysis with NAFLD acting as a mediator, obesity was associated with CAC in both male and 
female participants (Supplementary Fig. S1 and Supplementary Table S2).
Discussion
The present study showed that NAFLD was significantly associated with CAC in a large, health-screening popu-
lation without previous CVD history after multiple adjustments including those for known CVD risk factors and 
markers of liver disease. Moreover, in our subgroup analysis, the association between NAFLD and CAC seemed 
to be affected by sex and obesity status, indicating that NAFLD could be a notably influential risk factor for CAC, 






(n = 4420) P-value
Age (years) 54 (48–60) 54 (48–61) 54 (48–60) 0.051
Sex (male) 4309 (59.4) 2070 (72.9) 2239 (50.7) <0.001
Hypertension (yes) 1462 (20.1) 812 (28.6) 650 (14.7) <0.001
Diabetes (yes) 402 (5.5) 180 (6.3) 222 (5.0) 0.018
Dyslipidaemia (yes) 586 (8.1) 276 (9.7) 310 (7.0) <0.001
Current smoker (yes) 1026 (19.8) 453 (21.7) 573 (18.5) 0.005
Alcohol status (yes) 3143 (43.3) 1376 (66.0) 1769 (56.8) <0.001
BMI (kg/m2) 24.1 (22.0–26.3) 27.0 (25.9–28.8) 22.5 (20.9–23.8) <0.001
SBP (mmHg) 125 (114–135) 130 (120–139) 121 (111–132) <0.001
Fasting glucose (mg/dL) 97 (90–106) 100 (93–111) 95 (88–103) <0.001
eGFR (mL/min/1.73 m2) 95 (84–103) 94 (82–102) 96 (85–104) <0.001
LDL-cholesterol (mg/dL) 128 (106–153) 131 (108–158) 126 (104–149) <0.001
CRP (mg/L) 0.7 (0.3–1.5) 1.0 (0.5–2.0) 0.5 (0.3–1.1) <0.001
AST (IU/L) 24 (20–30) 26 (21–33) 23 (19–29) <0.001
ALT (IU/L) 23 (16–32) 28 (20–40) 20 (15–28) <0.001
γ-GT (IU/L) 24 (16–39) 31 (21–50) 20 (14–31) <0.001
NAFLD (yes) 3328 (45.8) 1974 (69.5) 1354 (30.6) <0.001
No steatosis 3931 (54.2) 864 (22.0) 3066 (78.0)
Mild steatosis 1604 (22.1) 771 (48.1) 833 (51.9)
Mild to moderate steatosis 284 (3.9) 164 (57.7) 120 (42.3)
Moderate steatosis 1054 (14.5) 720 (68.3) 334 (31.7)
Moderate to severe steatosis 171 (2.4) 131 (76.6) 40 (23.4)
Severe steatosis 215 (2.9) 188 (87.4) 27 (12.6)
Abdominal obesity (yes) 4698 (64.6) 2648 (93.3) 2050 (46.4) <0.001
CAC (yes) 2231 (30.7) 1087 (38.3) 1144 (25.9) <0.001
Table 1. Characteristics of the study participants classified by obesity status. Values are expressed as 
number (%) for categorical variables or as median (25th to 75th percentile) for numeric variables, unless 
noted otherwise. BMI, body mass index; SBP, systolic blood pressure; eGFR, estimated glomerular filtration 
rate; LDL, low-density lipoprotein; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; γ-GT, gamma-glutamyl transpeptidase; NAFLD, non-alcoholic fatty liver disease; CAC, 
coronary artery calcification.
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Previous studies showed that NAFLD was significantly associated with adverse CVD events in the general 
population32–38. Independent of traditional cardiovascular and metabolic risk factors, NAFLD has been reported 
to be associated with CAC5,8,39–42, which is closely correlated with the severity of atherosclerosis and directly 
proportional to increased cardiovascular event rates13,43. A recent large longitudinal cohort study demonstrated 
that NAFLD was significantly associated with the development of CAC independent of time-dependent BMI in 
participants with no history of CVD8. However, the Diabetic Heart Study showed that hepatic steatosis was not 
significantly correlated with coronary calcium in randomly selected participants, although it was correlated with 
visceral and subcutaneous fat after adjustment for age, race, sex, BMI, and diabetes status17. A study of postmeno-
pausal women showed a significant correlation between NAFLD and the prevalence of CAC, but this association 
was not statistically significant after adjustment19.
Through univariate analysis, the present study showed that NAFLD was significantly associated with CAC 
when all participants were considered. However, NAFLD showed different associations with CAC according to 
obesity status after adjustment for multiple risk factors. Notably, a significant association between NAFLD and 
CAC was only observed in non-obese participants, whereas the same was not true for obese participants.
A previous study reported that the prevalence of non-alcoholic steatosis and fibrosis is not significantly differ-
ent between non-obese and obese patients with NAFLD. Further, visceral obesity, as opposed to general obesity, 
may be associated with NAFLD in non-obese patients12. Ectopic fat accumulation, such as that in cases with 
visceral fat, epicardial adipose tissue, or NAFLD, has been proposed as a more important predictor of CVD than 
general fat accumulation44. Previous studies noted that epicardial adipose tissue has a positive correlation with 
CVD evaluated by non-invasive or invasive angiography and that it had a stronger correlation with CVD than 
other body fat distribution, especially in non-obese males45,46. Although non-obese patients with NAFLD may 
less frequently have clinically evident metabolic disorders than overweight or obese patients with NAFLD, they 
had an increased risk for metabolic disorders and should be prospectively evaluated11,12. A recent large cohort 
study using health-screening program data showed that CAC was more closely associated with NAFLD than 
with abdominal obesity in male participants. Although the mean CAC score was the highest in participants with 
abdominal obesity without NAFLD, subjects with NAFLD alone showed an increased risk for CAC, whereas sub-
jects with abdominal obesity alone showed an insignificantly increased risk for CAC in multivariate analysis5. Our 
Variables
All participants Obese participants Non-obese participants
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age 1.11 (1.10–1.12) <0.001 1.12 (1.10–1.13) <0.001 1.11 (1.10–1.12) <0.001
Male sex 3.24 (2.65–3.97) <0.001 3.59 (2.67–4.83) <0.001 2.88 (2.16–3.83) <0.001
Hypertension 1.82 (1.57–2.11) <0.001 1.65 (1.34–2.03) <0.001 2.06 (1.66–2.56) <0.001
Diabetes 1.82 (1.43–2.33) <0.001 1.70 (1.19–2.44) 0.004 1.98 (1.42–2.77) <0.001
Obesity 1.27 (1.08–1.49) 0.004
Abdominal obesity 1.12 (0.90–1.40) 0.298 1.26 (0.71–2.26) 0.428 1.19 (0.91–1.55) 0.216
NAFLD 1.23 (1.06–1.44) 0.007 1.20 (0.95–1.52) 0.122 1.25 (1.02–1.54) 0.034
eGFR 1.00 (0.99–1.01) 0.836 1.01 (1.00–1.02) 0.150 0.99 (0.99–1.00) 0.091
CRP 1.00 (0.99–1.02) 0.904 1.00 (0.98–1.01) 0.905 1.01 (0.99–1.04) 0.397
Current smoking 1.27 (1.07–1.51) 0.008 1.14 (0.88–1.48) 0.310 1.44 (1.13–1.84) 0.004
Alcohol status 1.06 (0.90–1.24) 0.517 1.18 (0.92–1.51) 0.192 0.95 (0.77–1.19) 0.678
AST 1.01 (1.00–1.02) 0.006 1.02 (1.00–1.03) 0.013 1.01 (1.00–1.02) 0.049
ALT 1.00 (0.99–1.00) 0.252 1.00 (1.00–1.00) 0.482 0.99 (0.98–1.00) 0.083
γ-GT 1.00 (1.00–1.00) 0.077 1.00 (1.00–1.00) 0.798 1.00 (1.00–1.01) 0.027
Table 2. Multivariate logistic regression analysis to determine risk factors affecting CAC. CAC, coronary 
artery calcification; NAFLD, non-alcoholic fatty liver disease; eGFR, estimated glomerular filtration rate; CRP, 
C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma-glutamyl 







Table 3. Interaction test results with the interaction terms for sex, obesity status, and NAFLD via binary 
logistic regression models for CAC. Model 1, adjusted for age, sex, hypertension, diabetes, and abdominal 
obesity; model 2, adjusted for model 1 plus current smoking, estimated glomerular filtration rate, low-density 
lipoprotein, and C-reactive protein; model 3, adjusted for model 2 plus aspartate aminotransferase, alanine 
aminotransferase, gamma-glutamyl transpeptidase, and alcohol status. NAFLD, non-alcoholic fatty liver 
disease; CAC, coronary artery calcification.
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data also indicated that NAFLD was an independent risk factor for CAC in all participants after multiple adjust-
ments for factors, including obesity and abdominal obesity. Moreover, the present study showed that NAFLD 
could mediate the association between obesity and CAC in both male and female participants.
One of the strengths of this study is that it determined the effects of NAFLD on CAC according to obesity 
status and sex using a three-way interaction effect and showed that the association between NAFLD and CAC 
was influenced by sex and obesity status. Therefore, we performed a subgroup analysis that showed that NAFLD 
was a notably influential risk factor for CAC in non-obese male participants, but not in obese male participants 
or female participants. These findings suggest that NAFLD may be a more important contributor to CAC in 
non-obese male populations than in female or obese male populations. Our results suggest that the use of multi-
ple comparisons might be another explanation for the observed difference among subgroups.
The mechanisms underlying the deleterious effects of NAFLD on CVD outcomes are not clear. Insulin resist-
ance, oxidative stress, altered lipoprotein metabolism and adipokine levels, and chronic inflammation have been 
shown to be associated with the development of accelerated atherosclerosis in patients with NAFLD5,32,38,47. 
Further research is needed to unveil more specific mechanisms by which NAFLD may contribute to the develop-
ment and progression of atherosclerosis21.
This study has several limitations. First, our study was cross-sectional in design. Therefore, the precise rela-
tionship between NAFLD and CAC remains unclear based on obesity status. Prospective studies should be 
performed to determine whether the association between NAFLD and CAC differs according to obesity status. 
Second, NAFLD was determined using ultrasonography rather than histologic evaluation. However, ultrasonog-
raphy is widely used in the clinical setting and has been shown to be able to independently detect CVD38. Third, 
the assessments for smoking and alcohol use were based on a self-administered structured questionnaire during 
a health check-up program. Finally, diagnostic coronary angiography could not be performed to confirm the 
relationship between NAFLD and the presence of CAC.
In conclusion, NAFLD was significantly associated with CAC in healthy-screening program participants. 
However, this association appeared to differ according to sex and obesity status. Future studies on NAFLD should 
focus on non-obese male participants who are most likely to benefit from intensive lifestyle modification and 
pharmacological treatment to decrease CVD risk.
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